CONNECTICUT CARE · WEIGHT-CARE MEDICINES
Sort out weight-care medicines
Ask which exact medicine is offered, its form—tablet or injection—and the health problem it is intended to treat.
Get the product and the purpose clear
The US medicine agency is the FDA: the Food and Drug Administration.
| Name or description | What the record says | What remains to ask |
|---|---|---|
| Semaglutide (Ozempic, Wegovy) | As of September 2026, Ozempic has products approved for type 2 diabetes, while Wegovy has products approved for weight care. | Which product, form and treatment purpose? |
| Tirzepatide (Mounjaro, Zepbound) | As of September 2026, Mounjaro has approval for type 2 diabetes, while Zepbound has approval for weight care. | Why does this product fit my health problem? |
| A compounded version | A medicine prepared to order lacks FDA approval, as of September 2026. | What medical need requires a change to the ready-made medicine? |
A short explanation of the name you may hear
Your body makes GLP-1, a hormone that carries a chemical message to help control blood sugar and appetite; semaglutide and similar medicines copy its action.
Rather than starting with a drug menu, ask what the assessment finds and which options fit that finding.
Why a shortage story may be out of date
In September 2026, FDA’s national shortage list does not include semaglutide or tirzepatide injections.
As of September 2026, a medicine does not qualify for FDA’s national shortage list just because a local pharmacy has run out.
As of September 2026, FDA can still treat a semaglutide injection mixed with a vitamin as a copy of the ready-made medicine.
Adding a vitamin does not by itself allow a pharmacy to make a copy after the national shortage ends, under the September 2026 rules.
Ask what change is needed for your own medical care, and how the service has checked the copy rule.
Keep the generic and compounding questions apart
Generic medicines are approved copies of brand-name medicines; a generic name is just the ingredient’s name.
As of September 2026, no generic semaglutide or tirzepatide has US approval that allows it to be sold; one semaglutide copy has tentative approval, which is not yet permission to sell it.
As of September 2026, liraglutide (Victoza, Saxenda) has generic products, including some approved for weight care.
In September 2026, FDA’s position is that compounding retatrutide or cagrilintide is barred by federal law.
Ask which approval record applies to the offered product. A lower price and a familiar ingredient name leave that question open.